SB1 Markets repeats its Neutral rating on medical technology company Medistim and raises the price target to 260 Norwegian kronor from 230.
The increase is justified by rising valuations in the sector and a 6 percent upward revision to the earnings forecast for 2026.
SB1 expects annual sales growth of 9–10 percent and improved margins. At the same time, the stock trades at a P/E ratio of 27 for 2027, compared with 18 for comparable companies. The bank believes the premium is justified by Medistim’s stronger growth and profitability.
